DDInter649 DDInter1435
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile,
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP3A4
Enzalutamide {u} (Compound) upregulates {v} (Gene) RPL39L
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Enzalutamide {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Enzalutamide (Compound) resembles Nilutamide (Compound)
Enzalutamide (Compound) resembles Bicalutamide (Compound)
Enzalutamide (Compound) binds CYP3A4 (Gene)
Enzalutamide (Compound) upregulates RPL39L (Gene)
Enzalutamide (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Enzalutamide (Compound) causes Musculoskeletal pain (Side Effect)
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir